Transduction of human pancreatic tumor cells with vesicular stomatitis virus G-pseudotyped retroviral vectors containing a herpes simplex virus thymidine kinase mutant gene enhances bystander effects and sensitivity to ganciclovir

Cancer Gene Therapy

Volumn 7, Issue 6, 2000, Pages 927-938

  Howard, Bradley D ^a   Boenicke, Lars ^a   Schniewind, Bodo ^a   Henne Bruns, Doris ^a   Kalthoff, Holger ^a,b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

Herpes simplex virus thymidine kinase gene therapy; Human pancreatic tumor cells; Humanized enhanced green fluorescent protein; Mutant herpes simplex virus thymidine kinase genes; Pseudotyping; Retroviruses

Indexed keywords

GREEN FLUORESCENT PROTEIN; THYMIDINE KINASE; VIRUS VECTOR;

ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; FLUORESCENCE; GENE THERAPY; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; MURINE LEUKEMIA VIRUS; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; RETROVIRUS; SOUTHERN BLOTTING;

ANIMALIA; FELIS CATUS; HERPES; MOLONEY MURINE LEUKEMIA VIRUS; MURINAE; SIMPLEXVIRUS; UNIDENTIFIED RETROVIRUS; VESICULAR STOMATITIS VIRUS;

EID: 0033920755     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700180     Document Type: Article

References (45)

1. Yeo CJ, Cameron JL. Prognostic factors in ductal pancreatic cancer. Langenbecks Arch Surg. 1998:129-133.
2. Hodgson CP. Retro-vectors for human gene therapy. Medical Intelligence Unit. New York: RG Landes and Company, 1996:25-51.
3. Miller AD. Cell surface receptors for retroviruses and implications for gene transfer. Proc Natl Acad Sci USA. 1996;93:11407-11413.
4. Finer M, Dull TJ, Qin L, Farson D, Roberts MR. kat: a high efficiency retroviral transduction system for primary human T lymphocytes. Blood. 1994;83:43-50.
5. Cone RD, Mulligan RC. High-efficiency gene transfer into mammalian cells: generation of helper-free recombinant retrovirus with broad mammalian host range. Proc Natl Acad Sci USA. 1984;20:6349-6353.
6. Danos O, Mulligan RC. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc Natl Acad Sci USA. 1988;85:6460-6464.
7. Battini JL, Danos O, Heard JM. Receptor-binding domain of murine leukemia virus envelope glycoproteins. J Virol. 1995;69:713-719.
8. Wilson C, Retiz MS, Okayama H, Eiden MV. Formation of infectious hybrid virions with gibbon ape leukemia virus and human T-cell leukemia virus envelope glycoproteins and the gag and pol proteins of Moloney murine leukemia virus. J Virol. 1989;63:2374-2378.
9. Cosset FL, Takeuchi Y, Battini JL, Weiss RA, Collins MK. High-titer packaging cells producing recombinant retroviruses resistant to human serum. J Virol. 1995;69:7430-7436.
10. Burns JC, Friedmann T, Driever W, Burrascano M, Yee JK. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration of very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci USA. 1993;90:8033-8037.
11. Wimer E. In: Wimer E, ed. Cellular Receptors for Animal Retroviruses. Plainview, NY: Cold Spring Harbor Laboratory Press; 1994:1-13.
12. Hunter E. In: Coffin JM, Hughes SH, Varmus H, eds. Retroviruses. Plainview, NY: Cold Spring Harbor Laboratory Press; 1997:71-120.
13. Tailor CS, Friedmann T, Driever W, Burrascano M, Yee JK. Cloning and characterization of a cell surface receptor for xenotropic and polytropic murine leukemia viruses. Proc Natl Acad Sci USA. 1999;96:927-932.
14. Cusack JC, Tanabe KK. Cancer gene therapy. Surg Oncol Clin N Am. 1998;7:421-469.
15. Miller DG, Edwards RH, Miller AD. Cloning of the cellular receptor for amphotropic murine retroviruses reveals homology to that for gibbon ape leukemia virus. Proc Natl Acad Sci USA. 1994;91:78-82.
16. Van Zeijl M, Johann SV, Closs E, et al. An amphotropic virus receptor is a second member of the gibbon ape leukemia virus receptor family. Proc Natl Acad Sci USA. 1994;91:1168-1172.
17. Kavanaugh MP, Miller DG, Zhang W, et al. Cell surface receptors for gibbon ape leukemia virus and amphotropic murine retrovirus are inducible sodium-dependent phosphate symporters. Proc Natl Acad Sci USA. 1994;91:7071-7075.
18. Rasko J, Battini JL, Gottschalk RJ, Mazo I, Miller AD. The RD 114/simian type D retrovirus receptor is a neutral amino acid transporter. Proc Natl Acad Sci USA. 1999;96: 2129-2134.
19. Schlegel R, Tralka TS, Willingham MC, Pastan I. Inhibition of VSV binding and infectivity by phosphatidylserine: is phosphatidylserine a VSV-binding site? Cell. 1983;32: 639-646.
20. Lin S, Gaiano N, Culp P, et al. Integration and germline transmission of a pseudotyped retroviral vector in zebrafish. Science. 1994;265:666-669.
21. Liu ML, Winther BL, Kay MA. Pseudotransduction of hepatocytes by using concentrated VSV-G Moloney murine leukemia virus-derived retrovirus vectors: comparison of VSV-G and amphotropic vectors for hepatic gene transfer. J Virol 1996;70:2497-2502.
22. Matsubara T, Beeman RW, Shike H, et al. Pantropic retroviral vectors integrate and express in cells of the malaria mosquito, Anopheles gambiae. Proc Nad Acad Sci USA. 1996;93:6181-6185.
23. Yee JK, Miyanohara A, LaPorte P, Bouic K, Burns JC, Friedmann T. A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes. Proc Natl Acad Sci USA. 1994;91:9564-9568.
24. Chen ST, Iida A, Guo L, Friedmann T, Yee JK. Generation of packaging cell lines for pseudotyped retroviral vectors of the G protein of vesicular stomatitis virus by using a modified tetracycline-inducible system. Proc Natl Acad Sci USA. 1996;93:10057-10062.
25. Ory D, Neugeboren BA, Mulligan RC. A stable human-derived packaging cell line for production of high-titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc Natl Acad Sci USA. 1996;93:11400-11406.
26. Faulds D, Heel RC. Ganciclovir. Drugs. 1990;39:596-638.
27. Furman PA, McGuirt PV, Keller PM, Fyfe JA, Elion GB. Inhibition by acyclovir of cell growth and DNA synthesis of cells biochemically transformed with herpes virus genetic information. Virology. 1980;102:420-430.
28. Reid R, Eng-Chun M, Eng-Shang H, Topal MD. Insertion and extension of acyclic, dideoxy, and ara nucleotides by herpesviridae, human a, and human β polymerases. J Biol Chem. 1988;263:3898-3904.
29. Moolten FL. Drug sensitivity ("suicide") genes for selective cancer gene therapy. Cancer Gene Ther. 1994;1:279-287.
30. Black ME, Newcomb TG, Wilson H-MP, Loeb LA. Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy. Proc Natl Acad Sci USA. 1996;93:3525-3529.
31. Yang L, Hwang R, Chiang Y, Gordon EM, Anderson WF, Parekh D. Mechanisms for ganciclovir resistance in gastrointestinal tumor cells transduced with a retroviral vector containing the herpes simplex virus thymidine kinase gene. Clin Cancer Res. 1998;4:731-741.
32. Bi WL, Parysek LM, Warnick R, Stambrook PJ. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV-tk retroviral gene therapy. Hum Gene Ther. 1993;4:725-731.
33. Denning C, Pitts JD. Bystander effects of different enzyme-prodrug systems for cancer gene therapy depend on different pathways for intercellular transfer of toxic metabolites, a factor that will govern clinical choice of appropriate regimes. Hum Gene Ther. 1997;8:1825-1835.
34. Mesnil M, Piccoli C, Tiraby G, Willecke K, Yamasaki H. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci USA. 1996;93:1831-1835.
35. Porter CD, Collins MK, Tailor CS, et al. Comparison of efficiency of infection of human gene therapy target cells via four different retroviral receptors. Hum Gene Ther. 1996;7:913-919.
36. Okabe T, Yamaguchi N, Ohsawa N. Establishment and characterization of a carcinoembryonic antigen (CEA)-producing cell line from a human carcinoma of the exocrine pancreas. Cancer. 1983;51:662-668.
37. Morgan RT, Woods LK, Moore GE, Quinn LA, McGavran L, Gordon SG. Human cell line (COLO 357) of metastatic pancreatic adenocarcinoma. Int J Cancer Res. 1980;25:591-598.
38. Ausubel FM, et al. Transfection of DNA into eukaryotic cells. In: Current Protocols in Molecular Biology. New York: John Wiley and Sons; 1994:9.0.1.-9.17.3.
39. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning. 2nd ed. Plainview, NY: Cold Spring Harbor Laboratory Press; 1989.
40. Smiley WR, Laubert B, Howard BD, et al. Establishment of parameters for optimal transduction efficiency and antitumor effects with purified high-titer HSV-TK retroviral vector in established solid tumors. Hum Gene Ther. 1997;8:965-977.
41. Gallardo HF, Tan C, Ory D, Sadelain M. Recombinant retroviruses pseudotyped with the vesicular stomatitis virus-G glycoprotein mediate both stable gene transfer and pseudotransduction in human peripheral blood lymphocytes. Blood. 1997;90:952-957.
42. Movassagh M, Desmyter C, Baillou C, et al. High-level gene transfer to cord blood progenitors using gibbon ape leukemia virus pseudotype retroviral vectors and an improved clinically applicable protocol. Hum Gene Ther. 1998;9:225-234.
43. Davis JL, Witt RM, Gross PR, et al. Retroviral particles produced from a stable human-derived packaging cell line transduce target cells with very high efficiencies. Hum Gene Ther. 1997;8:1459-1467.
44. Sturtz FG, Waddell K, Shulok J, et al. Variable efficiency of the thymidine kinase/ganciclovir system in human glioblastoma cell lines: implications for gene therapy. Hum Gene Ther. 1997;8:1945-1953.
45. Lemoine NR. Chapter 15: Strategies for genetic intervention in pancreatic cancer. In: Neoptolemos JR, Lemoine NR, eds. Pancreatic Cancer. Oxford: Blackwell Science; 1996:181-193.